Mon.Oct 07, 2024

article thumbnail

Midyear Pharmacy Update: Evaluating the Impact of DIR Fees

Drug Topics

A roundtable session discussed the real-world implications of applying DIR fees at the point of sale rather than through retroactive clawback.

200
200
article thumbnail

2024 Nobel prize in medicine: Ruvkun, Ambros win for discovery of microRNA

STAT

LONDON — A pair of scientists who discovered a type of RNA molecule that helps control the activity of genes — allowing our cells to perform all their myriad of functions in different tissues throughout the body — won the 2024 Nobel Prize in medicine or physiology on Monday. The award went to Victor Ambros and Gary Ruvkun for their research into microRNA, which the Nobel committee described as a “groundbreaking discovery [that] revealed a completely new principle of g

145
145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Examining Barriers to Assessing and Treating Pain in Pediatric Patients

Drug Topics

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

187
187
article thumbnail

Emergency Prescription Assistance Program Deployed in North Carolina Following Hurricane Helene

Pharmacy Times

Eligible patients can receive a 30-day supply of covered drugs and medical supplies that can be renewed every 30 days for as long as an Emergency Prescription Assistance Program (EPAP) is active.

144
144
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Opinion: A global revolution in funding mental health care is coming

STAT

The conversation about the mental health crisis is loud, but at a standstill. Stuck on repeat around the challenges of accessing existing treatments, the situation can appear increasingly hopeless.  I see another future — one far more positive and exciting. We are on the cusp of a revolution in mental health science. In five years’ time, the mental health treatment landscape will look radically different.

144
144
article thumbnail

Florida hospitals again evacuating patients ahead of second hurricane in 2 weeks

Fierce Healthcare

A rapidly intensifying Hurricane Milton has Florida and its healthcare providers gearing up for another severe weather event less than two weeks after similar preparations for Hurricane Helene. | Facing a second major storm within two weeks, some hospitals on Florida's Gulf Coast are again closing up shop and transferring patients across the state.

Hospitals 140

More Trending

article thumbnail

FDA Grants Breakthrough Therapy Designation to Setrusumab for Osteogenesis Imperfecta

Pharmacy Times

Setrusumab could offer a rapid and clinically meaningful decrease in fracture rate in individuals with osteogenesis imperfecta.

FDA 139
article thumbnail

STAT+: Janet Woodcock, former FDA official, joins board of patient group focused on ‘rediscovering’ old drugs

STAT

An organization scouring thousands of existing drugs to see if any can cure hard-to-treat diseases has a powerful new ally: Janet Woodcock, who for decades was one of the most influential figures at the Food and Drug Administration. The group, Every Cure, is led by physician David Fajgenbaum, who has told his own story again and again: When he was a young medical student, he came down with a rare disease that turned his athletic, football-honed body bloated and weak and nearly killed him not onc

FDA 138
article thumbnail

AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'

Fierce Pharma

After winning a first-in-class nod for its two-drug inhaler Airsupra l | After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity.

Packaging 136
article thumbnail

Q&A: How California, now an epicenter for bird flu in dairy cattle, is monitoring the virus

STAT

From the earliest days of the H5N1 bird flu outbreak in dairy cattle, experts watching the evolving situation have worried about California.  The Golden State has the country’s largest concentration of dairy farms, roughly 1,100 herds. The concern has been if the virus got into California, the prospects for spread would be huge and containment a challenge.

132
132
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

UnitedHealth report calls out policy changes to accelerate shift to value-based care

Fierce Healthcare

The healthcare industry is making the push toward greater adoption of value-based care, yet it's not a secret that progress has been slow-moving. | The healthcare industry is making the push toward greater adoption of value-based care, yet it's not a secret that progress has been slow-moving. With that backdrop, UnitedHealth Group has released its latest "A Path Forward" report, which is a biennial look at progress in the shift to value.

130
130
article thumbnail

2024 Nobel Prize winner Gary Ruvkun on sharing credit and the future of microRNA

STAT

Gary Ruvkun is used to getting awards — but for him, the Nobel Prize is in a class of its own. “I’ve won 10 to 20 awards in the last 20 years, but never had a press conference with cameras and nothing like this,” Ruvkun, who along with Victor Ambros received the 2024 award in medicine or physiology on Monday, said at a press conference at Massachusetts General Hospital.

article thumbnail

Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case

Fierce Pharma

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.

124
124
article thumbnail

Treosulfan Improves Survival and Lowers Mortality Prior to Allo-HSCT in Patients With Myelofibrosis

Pharmacy Times

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

123
123
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

Pharmaceutical Technology

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

121
121
article thumbnail

Expert: Helping Fulfill Patients’ Needs is the Most Rewarding Part of Pharmacy

Pharmacy Times

Teresa Messick, PharmD discusses how meeting patients “where they are” and supporting them holistically through medication and beyond is the most rewarding part of the profession.

123
123
article thumbnail

STAT+: 12 people changing the course of the Chinese biopharma industry

STAT

From antibody-drug conjugates to immuno-oncology checkpoint inhibitors, China is the world’s most closely watched rising biotechnology power. The growth of China’s industry can be attributed to a number of factors, including beneficial state policies and fresh injections of funding. There has also been bold regulatory reform. Since 2015, the country’s National Medical Products Administration has issued one milestone regulation after another, greatly accelerating the process

Vaccines 119
article thumbnail

Exploring the CARMEN-LCO3 Trial: Tusamitamab Ravtansine vs Docetaxel in Advanced Non-Squamous NSCLC

Pharmacy Times

At the 2024 World Conference on Lung Cancer, Benjamin Besse, MD, PhD, discussed the findings of the phase 3 CARMEN-LCO3 trial, which led to the discontinuation of the study drug by the manufacturer.

123
123
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Mpox shows need for new approaches to therapeutic antibody research

pharmaphorum

The recent Mpox outbreak highlights the urgent need for new approaches to therapeutic antibody research. Discover how the World Health Organization (WHO) and CDC are responding to this public health crisis.

119
119
article thumbnail

Zodasiran Demonstrated Safety, Efficacy in Treatment of Patients With Mixed Hyperlipidemia

Pharmacy Times

Zodasiran is an RNA interference therapy targeting the ANGPTL3 loss-of-function mutation.

123
123
article thumbnail

Virtual diabetes care providers score legislative win, turn focus to full passage

Fierce Healthcare

Tucked within bipartisan telehealth legislation that passed out of a House committee in September is the Prevent Diabetes Act, a bill that would expand Medicare coverage for virtual diabetes preven | Companies like Omada Health and Noom are urging Congress to pass the Prevent Diabetes Act to expand access to virtual diabetes prevention for Medicare beneficiaries.

116
116
article thumbnail

Managing the UK's ADHD medication supply crisis with accessible technology support

pharmaphorum

Learn how accessible technology support can help in managing the UK's ADHD medication supply crisis within the NHS, and improve outcomes for patients.

115
115
article thumbnail

Real-Time Prescription Benefits Improved Fill Rates, Decreased Copays

Drug Topics

Researchers analyzed the impact of real-time prescription benefits on prescribing patterns by evaluating subsequent fill rates and copay costs.

112
112
article thumbnail

MicroRNA pioneers win Nobel Prize for medicine

pharmaphorum

Victor Ambros and Gary Ruvkun have shared this year's Nobel Prize in Physiology or Medicine for their discovery of microRNA

111
111
article thumbnail

In This Issue: Total Pharmacy October 2024

Drug Topics

See what’s trending in pharmacy with a preview of the Total Pharmacy October issue.

112
112
article thumbnail

Advancements in early detection and innovative therapies targeting tau pathology

pharmaphorum

Stay updated on the latest advancements in early detection and innovative therapies targeting tau pathology in Alzheimer’s disease. Learn more about the cutting-edge research and treatments available.

110
110
article thumbnail

AstraZeneca’s Airsupra Significantly Reduces Risk of Severe Exacerbations in Patients with Asthma

Drug Topics

The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

112
112
article thumbnail

NHS England to be given a bigger role in GP data sharing

pharmaphorum

UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific researchers, taking on some of the responsibility held by GPs. The minister told the Royal College of General Practitioners (RCGP) annual conference that, while many UK patients have given their consent for their data to be shared with studies run by the likes of the UK Biobank, Genomics England, and Our Future Health, they "still see, far too often, that this data is not shared

110
110
article thumbnail

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

Pharmaceutical Technology

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.

105
105
article thumbnail

Discover the mentor in you!

pharmaphorum

Learn how Oliver Stohlmann nurtures the mentor in you, emphasising values like integrity. Discover how you can become a mentor and make a difference in someone's life.

106
106
article thumbnail

STAT+: Scholar Rock drug for spinal muscular atrophy succeeds in late-stage study

STAT

The biotech company Scholar Rock reported Monday that its experimental medicine improved motor function in patients with a muscle-wasting disease called spinal muscular atrophy, paving the way for the likely approval of the drug. In a year-long Phase 3 trial, the company tested the drug, called apitegromab, on top of existing treatments for the disease.

105
105
article thumbnail

First real-world study reveals encouraging efficacy for cell therapy

European Pharmaceutical Review

New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials. For example, of the 236 patients who received infusions of ciltacabtagene autoleucel (cilta-cel), data shows that 89 percent responded to the treatment.

FDA 105
article thumbnail

AZ extends cardiovascular pipeline with $2bn CSPC deal

pharmaphorum

AstraZeneca pays $100m upfront for rights to an oral lipoprotein(a) drug developed by Chinese biotech CSPC Pharmaceutical.

105
105